Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant
carbapenem-resistant Enterobacteriaceae
carbapenem-resistant organism
hospital-acquired pneumonia
polymyxin B
tigecycline
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
09
2021
accepted:
13
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
It is not clear whether polymyxin B/tigecycline (PMB/TGC) combination is better than PMB or TGC alone in the treatment of hospital-acquired pneumonia (HAP) caused by carbapenem-resistant organisms (CROs). We conducted a multicenter, retrospective cohort study in patients with HAP caused by CROs. The primary outcome was 28-day mortality, and the secondary outcomes included clinical success and the incidence of acute kidney injury (AKI). Multivariate Cox regression analysis was performed to examine the relationship between antimicrobial treatments and 28-day mortality by adjusting other potential confounding factors. A total of 364 eligible patients were included in the final analysis, i.e., 99 in the PMB group, 173 in the TGC group, and 92 in the PMB/TGC combination group. The 28-day mortality rate was 28.3% (28/99) in the PMB group, 39.3% (68/173) in the TGC group, and 48.9% (45/92) in the PMB/TGC combination group ( The appropriate PMB/TGC combination was not superior to appropriate PMB therapy in the treatment of HAP caused by carbapenem-resistant
Identifiants
pubmed: 35755062
doi: 10.3389/fmed.2022.772372
pmc: PMC9226555
doi:
Types de publication
Journal Article
Langues
eng
Pagination
772372Informations de copyright
Copyright © 2022 Chang, Wang, Zhao, Yang, Wu, Sun, Huang, Cheng, Chen, Song, Chen, Chen, Gan, Ma, Xing, Wang, Gu, Zou and Cao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2015 Jun;43(6):1194-204
pubmed: 25793437
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20
pubmed: 23290507
Int J Antimicrob Agents. 2013 May;41(5):463-7
pubmed: 23537581
Open Forum Infect Dis. 2017 Aug 16;4(3):ofx176
pubmed: 29026867
Medicine (Baltimore). 2016 Mar;95(11):e3126
pubmed: 26986165
Clin Infect Dis. 2018 Nov 28;67(12):1803-1814
pubmed: 30052813
Front Microbiol. 2020 Oct 21;11:533209
pubmed: 33193122
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
Open Forum Infect Dis. 2015 May 05;2(2):ofv050
pubmed: 26125030
Antimicrob Agents Chemother. 2014;58(2):874-9
pubmed: 24277022
Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601
pubmed: 24982065
J Antimicrob Chemother. 2014 Sep;69(9):2305-9
pubmed: 24872346
Clin Microbiol Infect. 2021 Jan 6;:
pubmed: 33359542
J Antimicrob Chemother. 2017 Jan;72(1):29-39
pubmed: 27624572
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Nat Microbiol. 2019 Oct;4(10):1627-1635
pubmed: 31209306
Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1003-1022
pubmed: 33403565
Clin Microbiol Infect. 2018 Jun;24(6):630-634
pubmed: 28970161
Lancet Infect Dis. 2017 Jul;17(7):726-734
pubmed: 28442293
Clin Microbiol Infect. 2014 Feb;20(2):O117-23
pubmed: 23992130
Clin Microbiol Infect. 2018 Aug;24(8):908.e1-908.e7
pubmed: 29108947
Clin Microbiol Infect. 2018 Oct;24(10):1070-1076
pubmed: 29410094
Can J Infect Dis Med Microbiol. 2008 Jan;19(1):19-53
pubmed: 19145262
Front Microbiol. 2019 Jan 30;10:80
pubmed: 30761114
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
Clin Infect Dis. 2013 Aug;57(3):349-58
pubmed: 23616495
Clin Microbiol Infect. 2008 Sep;14(9):816-27
pubmed: 18844682
JAMA. 2015 Oct 13;314(14):1479-87
pubmed: 26436831
Int J Infect Dis. 2015 Oct;39:25-33
pubmed: 26283551
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
N Engl J Med. 2017 Jun 8;376(23):2235-2244
pubmed: 28528569
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40
pubmed: 16080071
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Int J Antimicrob Agents. 2015 Jan;45(1):8-18
pubmed: 25465524
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Pharmacotherapy. 2019 Jan;39(1):10-39
pubmed: 30710469
Clin Infect Dis. 2010 Jan 15;50(2):229-38
pubmed: 20025527
Curr Opin Infect Dis. 2020 Dec;33(6):482-494
pubmed: 33009141
Virulence. 2017 May 19;8(4):460-469
pubmed: 27593176
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Clin Infect Dis. 2012 Jun;54(12):1699-709
pubmed: 22467668